Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

786.26 -1.06 (-0.13%)

Streaming Delayed Price Updated: 3:31 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

58 59 Next >

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

November 03, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug ↗

November 02, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate

Via Benzinga

Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers ↗

November 02, 2023

The launch of high-dose Eylea is off to a strong start in the U.S.

Via Investor's Business Daily

US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple ↗

November 02, 2023

After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick.

Via Benzinga

Topics Economy

Regeneron Pharmaceuticals Unusual Options Activity ↗

November 01, 2023

Via Benzinga

$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

October 31, 2023

Via Benzinga

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Via The Motley Fool

Regeneron Reports Third Quarter 2023 Financial and Operating Results

November 02, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

November 01, 2023

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech ↗

November 01, 2023

Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.

Via Talk Markets

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today ↗

October 19, 2023

Via Benzinga

Earnings Scheduled For November 2, 2023 ↗

November 02, 2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

Via Benzinga

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer ↗

October 30, 2023

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.

Via Benzinga

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff ↗

October 27, 2023

The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.

Via InvestorPlace

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

October 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

IBD's 100 Best ESG Companies For 2023 ↗

October 27, 2023

The companies on our list combine high sustainability scores and top stock ratings.

Via Investor's Business Daily

Regeneron Announces Investor Conference Presentations

October 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Stock-Split Watch: Could These 2 Growth Stocks Be Next? ↗

October 25, 2023

Neither company has discussed it, at least not yet.

Via The Motley Fool

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

October 22, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

October 21, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

October 20, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.